EP2173316A2

EP2173316A2 - Use of at least one oxime derivative of 3,5-seco-4-norcholestane as antioxidants

Info

Publication number: EP2173316A2
Application number: EP08835696A
Authority: EP
Inventors: Rebecca Pruss; Cyrille Drouot
Original assignee: Trophos SA
Current assignee: Trophos SA
Priority date: 2007-07-25
Filing date: 2008-07-24
Publication date: 2010-04-14
Also published as: JP2010534228A; WO2009044011A3; AU2008306755A1; BRPI0814667A2; MX2010000913A; US20100267837A1; CA2694148A1; AU2008306755B2; WO2009044011A2; RU2476225C2; NZ582647A; RU2010106609A; FR2919182A1; FR2919182B1; US8338488B2

Abstract

The invention relates to the use of at least one oxime derivative of 3,5-seco-4-norcholestane as antioxidants in the cosmetics and food fields, and as antioxidant preservatives that can be used, in particular, in cosmetic, food and pharmaceutical products.

Description

Use of at least one oxime derivative of 3,5-seco-4-nor-cholestane as antioxidants

The present invention relates to the use of at least one oxime derivative of 3,5-seco-4-nor-cholestane for their antioxidant property. More particularly, the present invention relates to the use of at least one oxime derivative of 3,5-seco-4-nor-cholestane as antioxidants in the cosmetic and food fields, and as antioxidant preservatives that can be used in particular in cosmetic and food products. , and pharmaceuticals. Oxidative stress is one of the biological consequences of the body's use of oxygen. It results in the formation of free radicals in the cells. Free radicals, if uncontrolled, can quickly react with molecules in their surroundings, giving rise to toxic compounds that can interfere with normal physiological processes. These substances can lead to cellular damage if the antiradical defenses are not sufficient. More and more studies show that reactive oxygen species play an important role in multiple biological processes and in particular in the development of multiple human pathologies, and in aging. The cumulative effects of these reactions can overwhelm normal mechanisms of cell repair.

The role of cell oxidation on aging and particularly cutaneous aging, whether intrinsic or extrinsic, in particular photoinduced, is known. Skin aging is reflected in various clinical signs, including the appearance of fine lines and deep wrinkles, which increases with age. In addition, the appearance of the skin or scalp deteriorates. The complexion of the skin is generally modified and it can exist on certain areas of the skin diffuse irritations and sometimes telangiectasias.

Another clinical sign of aging is the dry, rough appearance of the skin, which is essentially due to increased desquamation. Finally, there is a loss of firmness and tonicity of the skin which, as for wrinkles and fine lines, is at least partly explained by a dermal and epidermal atrophy and a flattening of the formation. We therefore see that clinical signs of skin aging result essentially from a dysfunction of the main biological mechanisms involved in the skin.

Preventing or treating skin aging, whether intrinsic or extrinsic, and the clinical signs described above, is to maintain or improve the appearance of the skin or scalp.

Various antioxidants capable of preventing or treating cutaneous aging are described in the state of the art.

Antioxidants are substances that neutralize free radicals or their actions. Thus, they help in protecting cells against free radical damage.

Among the natural antioxidant molecules are, for example, vitamins (A, E and C in particular), carotenoids (such as beta-carotene), polyphenols, and trace elements (such as selenium, copper and zinc). . The beneficial effect of an exogenous supply of antioxidant to limit oxidative stress and enhance the antioxidant defense, by ingestion, is known. Recent scientific evidence has shown that in some animal species the administration of antioxidants effectively curbs the aging process and increases the longevity of the animal. It is thus sometimes beneficial, to allow the body to function normally, to ingest components having antioxidant action in sufficient quantity.

Antioxidants also have a beneficial effect when they are applied to the skin, they are indeed used in cosmetics. The use of antioxidants as preservatives in various types of oxidation-sensitive products is also known.

However, the compounds used as antioxidants are sometimes inadequate or have insufficient action. It is known, for example, that tocopherol, which is a reference product in this field, is sensitive to light and requires particular preservation means.

It therefore remains a real need for antioxidant compounds, and it would be interesting to have new antioxidants with a powerful antioxidant activity and which would have a beneficial effect in the cosmetic field, in the food field, and also an effect on the preservation of products.

The present invention responds to this demand for potent antioxidant compounds since it relates to the use of at least one oxime derivative of 3,5-seco-4-nor-cholestane as an antioxidant, which are potent antioxidants. Indeed, the inventors have now shown the potent antioxidant role of at least one oxime derivative of 3,5-seco-4-nor-cholestane, and in particular the oxime of 3,5-seco-4-nor-cholestane. lipid peroxidation and also vis-à-vis substances likely to undergo thermo-or photo-induced oxidation reactions (such as proteins, sugars, pigments, vitamins, polymers).

This is why the present invention relates to the use of at least one oxime derivative of 3,5-seco-4-nor-cholestane as an antioxidant.

According to the invention, the term "antioxidant" refers to the ability of a compound to reduce the damage caused by free radicals: in the body, as an active ingredient in the cosmetic field and in the food field, and

- in any type of product requiring it to be better preserved, as a preservative.

Any use of the compounds as an active ingredient for a therapeutic application is excluded.

In addition to their excellent antioxidant properties, these compounds have the following advantages:

- their synthesis is feasible on the scale of several kilograms without industrial problems. - because they are powerful antioxidants, the required dose is very low;

- these compounds do not absorb in the UV / visible, they do not interfere with conventional solar products that absorb UV radiation and do not present a risk of chemical instability in this wavelength range; these compounds are in the form of crystalline powder and are very well preserved at room temperature, without any degradation for at least 12 months;

they have good solubility in fats; they are colorless, tasteless and odorless, which is an advantage for use in the food and cosmetic fields in particular;

- they are bioavailable, making them compounds that can be expected to exhibit systemic activity orally; The antioxidant properties of the compounds of the invention recommend their use in the cosmetic field.

Thus, a first aspect of the invention is the use of at least one oxime derivative of 3,5-seco-4-nor-cholestane to protect the skin.

The skin is especially the place of aggression of extrinsic and intrinsic toxic factors. Extrinsic factors include, for example, ultraviolet radiation, wind, low humidity, abrasives and strong surfactants.

Intrinsic factors include chronological aging and biochemical changes in the skin.

There is a cause-and-effect relationship between repeated UV exposure and premature aging of the skin. Excessive exposure to the sun contributes to a premature decrease in the quality and quantity of elastin and collagen in the skin, and to hypertrophy of the epidermis. These changes are manifested by typical signs of aging, such as wrinkles, loss of elasticity, dryness of the skin and increased frequency of blemishes, and benign or malignant neoplasia.

The compounds of the present invention are capable of providing effective protection against factors that cause the appearance of wrinkles and other histological changes associated with aging of the skin.

It is therefore also one of the objects of the invention to use the antioxidant properties of the compounds according to the invention on the symptoms of UV aging, that is to say on the damage on the skin which appears as the result of repeated exposure to the sun to prevent, erase and treat wrinkles, fine lines of the skin, and / or fight against sagging skin and / or subcutaneous; and / or improve the texture of the skin and revive the radiance of the skin; and / or decrease the pore sizes of the skin.

The advantageous properties of the compounds of the invention, their zero absorption in the spectrum of UVA and UVB, also justify their use in a cream for protection against solar radiation, without any risk of disrupt the action of specially selected components for their UV absorption. The compounds of the invention are capable of capturing the activated form of oxygen by solar radiation. This activated form of oxygen, called singlet oxygen, is the reactive entity at the origin of cellular disturbances. Another aspect of the invention consists in the use of the compounds of the invention in cleansing and / or make-up removing products, as well as in products for protecting the skin and / or the hair against the side effects of UV radiation. .

The antioxidant properties of at least one oxime derivative of 3,5-seco-4-nor-cholestane also recommend their use in the food field as a dietary supplement. It is therefore within the scope of the invention to use the compounds of the invention as antioxidants in the food field.

By antioxidant in the food field is meant in the present invention, a compound which, in pure form or in admixture with various carriers and / or other acceptable food additives, may be in powder form, in the form of capsules, tablet or other solid form that may optionally comprise a lipid phase, aqueous or be in solution or oral suspension. Advantageously, the compound can be consumed alone, between meals, or during meals.

Advantageously, it can be consumed during meals, as a dietary supplement, associated with other foods. Preferably it will be incorporated or sprinkled on a food. In practice, the foods may be simple or compound foods, and may be presented in any of the usual known forms of human nutrition. For the purposes of the present invention, the term "food" means any food which may be ingested, alone or accompanied, raw or cooked, whether or not prepared in any way, such as, for example, meat and meat products, seafood and freshwater products, milk and milk products, including infant formula, eggs and egg products, fruits and vegetables, cereals and cereal products, starchy foods such as pasta and rice, oils, vinegars and condiments, edible sauces and fats, sweet products, jams, jellies, compotes, spreads, confectionery, preserves and semi-preserves, soups, coffee, tea, beverages, pastry, cocoa, chocolate, ice cream, meal replacement, fresh, frozen or sterilized cooked meals and caterers, bread and bakery products. Thus, the compound can accompany any food without disturbing the taste and does not constitute a constraint for the consumer. His catch is assimilated to a culinary gesture. He does not remember taking medications or meal replacements. The compounds according to the invention can be frozen or, on the contrary, heated without losing their properties. The invention also relates to the use of the compounds according to the invention as antioxidant preservatives in various products, in particular cosmetic, food and pharmaceutical products.

By preservative is meant a compound which preserves a product of any physico-chemical alteration. It is known that the fatty substances and certain active substances used in the compositions, in particular cosmetic, dermatological, pharmaceutical or detergent compositions, tend to oxidize, even at ambient temperature, and that this oxidation makes them acquire new properties, especially olfactory properties. which are undesirable. We know for example that some soaps develop rancid, pungent and fruity odors after only a few weeks of storage in the air. However, these bad smells can be prevented or at least avoided during a much longer storage period, if one of the compounds of the invention is added to them. Similar effects have been observed with shampoos or shower or bath gels, creams and cosmetic milks, cosmetics or cleansing products for the skin or hair containing substances that can oxidize in the air and / or in the light. It is within the scope of the invention to use the compounds of the invention as antioxidants for the preservation of cosmetic, dermatological, pharmaceutical, detergent and perfuming products. Similarly, food products degrade under the action of air oxidation, which causes changes in texture, color and taste, and can render a food unfit for consumption.

The Applicant has discovered that the compounds of the invention to ensure a better preservation of the cosmetic or dermatological compositions comprising a fatty phase by avoiding the rancidity of unsaturated lipids contained therein, that they could also make it possible to avoid the oxidative degradation of active compounds contained in these compositions, such as the vitamin A or carotenoids.

It is therefore within the scope of this invention to use the compounds of the invention as preservatives, particularly for the preservation of properties. organoleptic and nutritional foods and beverages, including fruit juices.

The compounds according to the invention having strong antioxidant capacities, they can be used as antioxidant preservatives of any preparation based on lipids, including food products, cosmetics, dermatological, perfumes, detergents or pharmaceuticals.

The subject of the present invention is therefore the use of compounds according to the invention as preserving agents in products, in particular cosmetic or dermatological, and food products.

This is why the present invention relates to the use of at least one oxime derivative of 3,5-seco-4-nor-cholestane or one of its addition salts with acceptable acids, or the one of its esters or one of the addition salts of said esters with the acceptable acids, as antioxidants.

Advantageously, according to the invention, at least one compound of formula I is used.

in which

X and Y taken together represent an oxime group (= N-OH),

B represents a hydroxyl radical and C and D, which may be identical or different, represent a hydrogen atom or a linear or branched alkyl radical; comprising 1 to 4 carbon atoms, or B and C taken together represent a keto function and D a methyl, hydroxyl or methylamine radical, or B and C represent a hydrogen atom and D a methylamine radical, or B and C taken together represent an oxime group and D a methyl radical, and R represents a linear or branched alkyl radical comprising from 1 to 10 carbon atoms, or one of its addition salts with pharmaceutically acceptable acids, or one of its esters or one of the addition salts with pharmaceutically acceptable acids of said esters, as an antioxidant.

The compounds of formula I as defined above are described in the international application published March 16, 2006 under the number WO 2006/027454. As understood by those skilled in the art, a number of compounds of formula I which include one or more hydroxyl groups may be esterified. These esters and their addition salts with pharmaceutically acceptable acids are generally not directly active in themselves but are prodrugs for the corresponding hydroxyl analogues. These esters, which are metabolized in the human body, lead to the active compounds. These esters are also the subject of the present invention. Esters which introduce chemical functionalities such as sulphates, phosphates, acids and basic chains which increase aqueous solubility and bioavailability can be mentioned. Esters of compounds having a basic function such as dialkylglycine analogs with alkyls of 1 to 4 carbon atoms and most preferably dimethylglycine and diethylglycine and also methylpiperazine are preferred. Fatty acid esters or polyethylene glycol chain esters which increase the affinity for lipophilic phases may be mentioned. Saturated fatty acid chains of 3 to 18 carbons are preferred.

In the present application and in the following, the term "linear or branched alkyl radical of 1 to 4 carbon atoms denotes, for example, a methyl, ethyl, propyl or isopropyl radical, preferably a methyl or ethyl radical and particularly a methyl radical.

The term "linear or branched alkyl radical of 1 to 10 carbon atoms" denotes, for example, a 2-methyl-3-ethyl heptane, 3-ethyl heptane or 3-methyl heptane radical, preferably a 2-ethyl heptane radical and particularly the 2-methyl heptane radical of cholestane, shown below

More particularly, the compounds of formula

in which B, C, D, X and Y have the meaning already indicated. Among the compounds of formula I described above, mention is especially made of the compounds of formula I for which X together with Y represents an oxime function and also their esters and their addition salts with pharmaceutically acceptable acids.

More particularly, the above compounds for which - B represents a hydroxyl radical and C and D represent a hydrogen atom, or C and D represent 2 linear or branched alkyl radicals of 1 to 4 carbon atoms,

B represents together with C a keto function and D represents a methyl, hydroxyl or methyl amine radical; B represents a hydroxyl group; and C and D represent a hydrogen atom, or C and D represent 2 linear or branched alkyl radicals. from 1 to 4 carbon atoms, or C represents a hydrogen atom and D a linear or branched alkyl radical of 1 to 4 carbon atoms,

- B and C represent a hydrogen atom and D a methyl amino group. - B together with C represent an oxime group, and D represents a methyl radical, as well as their esters and their addition salts with pharmaceutically acceptable acids. We particularly remember

3,5-seco-4-nor-cholestan-5-one oxime-3-ol,

3,5-seco-4-nor-cholestan-5-one oxime-3-methyl alcohol, 3,5-seco-4-nor-cholestan-5-one oxime-3-dimethyl alcohol, or one of its addition salts with pharmaceutically acceptable acids, or one of its esters or one of the addition salts with pharmaceutically acceptable acids of said esters.

According to the invention, the addition salts with pharmaceutically acceptable acids may be for example salts formed with hydrochloric, hydrobromic, nitric, sulfuric, phosphoric acetic, formic, propionic, benzoic, maleic, fumaric, succinic or tartaric acids. citric, oxalic, glyoxylic, aspartic, alkane sulfonic acids such as methane or ethanesulphonic, arylsulphonic acids, such as benzene or paratoluene sulfonic acids, or carboxylic acids.

It is understood according to the invention that the oxime group represents the two isomers syn and anti in mixture or isolated.

Of course, according to the invention, it is possible to use the oxime derivative of 3,5-seco-4-nor-cholestane alone or as a mixture with at least one other oxime derivative of 3,5-seco-4-nor-cholestane. .

It is also possible to use the oxime derivatives of 3,5-seco-4-nor-cholestane alone or as a mixture as previously described in combination with one or more other compounds known for their antioxidant properties.

By way of examples, other compounds known for their antioxidant properties include compounds derived from the families of thiols and phenols and polyphenols, for example flavonoids (which are very common in plants), phenolic acids (in cereals, fruits and vegetables), tannins (in cocoa, coffee, tea, grapes, etc.), anthocyanins (especially in red fruits, β-carotene (provitamins A), tocopherols (vitamin E ) or its esters, such as alpha-tocopherol, gamma- tocopherol, delta-tocopherol; certain metal chelators or ascorbic acid and its esters such as sodium or calcium ascorbate; 5-6-1 -ascorbic diacetyl acid, 6-1-ascorbic palmityl acid, citric acid and citrates such as sodium, potassium and calcium; tartaric acid and tartrates such as those of sodium, potassium; butylhydroxyanisole and butylhydroxytoluol; octyl or dodecyl gallates; sodium, potassium or calcium lactates; lecithins; glutathione, or enzymes such as catalase, superoxide dismutases and some peroxidases.

The antioxidants that can be used in the composition of the invention may be natural or synthetic.

Thus, one of the aspects of the invention is therefore to provide an antioxidant cosmetic composition comprising at least in a cosmetically acceptable medium an effective amount of at least one oxime derivative of 3,5-seco-4-nor-cholestane. The invention also relates to a cosmetic composition for combating chronobiological aging and / or photoinduced comprising in a cosmetically acceptable medium an effective amount of at least one oxime derivative of 3,5-seco-4-nor-cholestane.

By cosmetically acceptable medium is meant compatible with the skin, the scalp, the mucous membranes, the nails and the hair.

The amount of oxime derivative of 3,5-seco-4-nor-cholestane or one of its derivatives which can be used according to the invention obviously depends on the desired effect and must be in an amount effective to produce the effect. antioxidant sought.

By way of example, the amount of at least one oxime derivative of 3,5-seco-4-nor-cholestane or its derivatives which can be used according to the invention can range, for example, from 0.01% to 30% and preferably from 0.1% to . % to 10% of the total weight of the composition.

The composition according to the invention obviously comprises a cosmetically acceptable carrier and may be in any of the galenical forms normally used, particularly for topical application.

Thus, the composition may in particular be in the form of an aqueous, hydroalcoholic or oily solution, an oil-in-water or water-in-oil or multiple emulsion, an aqueous or oily gel, a product anhydrous liquid, pasty or solid, an oil dispersion in an aqueous phase using spherules, these spherules may be polymeric nanoparticles such as nanospheres and nanocapsules or better lipid vesicles of ionic and / or nonionic type . This composition may be more or less fluid and have the appearance of a white or colored cream, an ointment, a milk, a lotion, a serum, a paste, a mousse . It can optionally be applied to the skin in the form of an aerosol. It can also be in solid form, and for example in the form of a stick. The composition of the invention can be used as a care product, as a cleaning product, as a makeup product or as a simple deodorant product.

In a known manner, the composition of the invention may also contain the usual adjuvants in the cosmetic and dermatological fields, such as hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic active agents, preservatives, solvents, perfumes, fillers, filters, pigments, chelating agents, odor absorbers and dyestuffs. The amounts of these various adjuvants are those conventionally used in the fields under consideration, and for example from 0.01% to 20% of the total weight of the composition. These adjuvants, depending on their nature, can be introduced into the fatty phase, into the aqueous phase, into the lipid vesicles and / or into the nanoparticles.

When the composition of the invention is an emulsion, the proportion of the fatty phase may range from 5% to 80% by weight, and preferably from 5% to 50% of the total weight ^'of the composition. The oils, emulsifiers and coemulsifiers used in the composition in emulsion form are chosen from those conventionally used in the field under consideration. The emulsifier and the coemulsifier are present in the composition in a proportion ranging from 0.3% to 30% by weight, and preferably from 0.5% to 20% of the total weight of the composition.

As oils that may be used in the invention, mention may be made of mineral oils, oils of vegetable origin (apricot oil, sunflower oil, shea butter), oils of animal origin, synthetic oils and oils. silicone and fluorinated oils (perfluoropolyethers). It is also possible to use fatty alcohols (cetyl alcohol), fatty acids and waxes (beeswax) as fatty substances.

^ y

As emulsifiers and coemulsifiers that can be used in the invention, mention may be made, for example, of fatty acid and polyethylene glycol esters such as PEG-40 stearate, PEG-100 stearate, fatty acid and polyol esters. such as glyceryl stearate and sorbitan tristearate.

As hydrophilic gelling agents, mention may in particular be made of carboxyvinyl polymers (carbomer), acrylic copolymers such as copolymers of acrylates / alkylacrylates, polyacrylamides, polysaccharides, natural gums and clays, and, as lipophilic gelling agents, it is possible to mention mention modified clays such as bentones, metal salts of fatty acids, hydrophobic silica and polyethylenes.

The composition may contain other hydrophilic active agents such as proteins or protein hydrolysates, amino acids, polyols, urea, allantoin, sugars and sugar derivatives, water-soluble vitamins, plant extracts and the like. hydroxy acids.

As lipophilic active agents, it is possible to use retinol (vitamin A) and its derivatives, tocopherol (vitamin E) and its derivatives, essential fatty acids, ceramides, essential oils, salicylic acid and its derivatives.

It is also possible to use according to the invention, in combination with at least one oxime derivative of 3,5-seco-4-nor-cholestane or of one of its derivatives, compounds chosen from:

- plant hormones (auxins); antibacterial agents such as macrolides, pyranosides and tetracyclines, and in particular erythromycin;

calcium antagonists, such as verapamil and diltiazem;

OH radical scavengers, such as dimethylsulfoxide;

extracts of plants such as Iridaceae or soybean extracts, which may then contain isoflavones or not;

extracts of micro-organisms, in particular bacterial extracts such as those of non-photosynthetic filamentous bacteria.

In the list above, other compounds may also be added, for example, openers of potassium channels such as diazoxide and minoxidil, spiroxazone, phospholipids such as lecithin, linoleic and linolenic acids, salicylic acid and its derivatives described in French patent FR 2 581 542, such as salicylic acid derivatives bearing an alkanoyl group having 2 to 12 carbon atoms at the 5-position of the benzene ring, hydroxycarboxylic or ketocarboxylic acids and its esters, lactones and its corresponding salts, anthralin, carotenoids, eicosatetraenoic and eicosatrienoic acids or its esters and amides, vitamin D and its derivatives. According to the invention, it is possible, inter alia, to associate the oxime derivative of 3,5-seco-4-nor-cholestane or one of its derivatives with other active agents intended in particular for the prevention and / or treatment skin conditions. Among these active agents, there may be mentioned by way of example: agents that modulate differentiation and / or proliferation and / or cutaneous pigmentation such as retinoic acid and its isomers, retinol and its esters, vitamin D and its derivatives, estrogens such as estradiol, kojic acid or hydroquinone; agents modulating bacterial adhesion to the skin and / or mucous membranes such as honey, especially acacia honey and certain sugar derivatives; antiparasitics, particularly metronidazole, crotamiton or pyrethroids; antifungals, in particular compounds belonging to the class of imidazoles such as econazole, ketoconazole or miconazole or its salts, polyene compounds, such as amphotericin B, compounds of the allylamine family, such as terbinafine, or octopirox - antiviral agents such as acyclovir; steroidal anti-inflammatory agents, such as hydrocortisone, betamethasone valerate or clobetasol propionate, or non-steroidal anti-inflammatory agents such as ibuprofen and its salts, diclofenac and its salts, acid acetylsalicylic acid, acetaminophen or glycyrrhetinic acid; anesthetic agents such as lidocaine hydrochloride and its derivatives; antipruritic agents such as thenaldine, trimeprazine or cyproheptadine; keratolytic agents such as alpha- and beta-hydroxycarboxylic acids or beta-ketocarboxylic acids, its salts, amides or esters and more particularly hydroxy acids such as glycolic acid, lactic acid, salicylic acid, citric acid and generally fruit acids, and n-octanoyl-5-salicylic acid; antiseborrhoeics such as progesterone; anti-dandruff such as octopirox or zinc pyrithione; - anti-acne drugs such as retinoic acid or benzoyl peroxide. substances such as substance P, CGRP or bradykinin antagonists or NO synthase inhibitors, compounds described as being active in the treatment of sensitive skin and having anti-irritant effects, in particular vis-à-vis irritating compounds that may be present in the compositions.

Thus, another subject of the invention relates to a composition comprising an effective amount of at least one oxime of 3,5-seco-4-nor-cholestane and at least one agent chosen from antibacterial, antiparasitic, antifungal and antiviral agents. , anti-inflammatory, antipruritic, anesthetic, keratolytic, anti-seborrhoeic, anti-dandruff, anti-acne, agents modulating differentiation and / or proliferation and / or skin pigmentation, substance P, CGRP or bradykinin antagonists or inhibitors NO synthase.

As actives, it is possible to use, in particular, moisturizers such as polyols (for example glycerine), vitamins (for example D-panthenol), anti-inflammatory agents, soothing agents (allantoin, cornflower water), filters UVA and UVB, matting agents (eg partially crosslinked polydimethylorganosiloxanes sold under the name KSG® by Shin Etsu), and mixtures thereof. It is also possible to add anti-wrinkle active agents, and especially tensor products such as vegetable proteins and their hydrolysates, in particular the soy protein extract sold under the name Eleseryl® by the company LSN or the oat derivative sold under the name Reductine® by the company Silab.

Other characteristics and advantages of the invention will emerge more clearly from the examples and from the appended FIG. 1 which follow, given by way of illustration and not limitation. In what follows or what precedes, the proportions are given in percentage by weight, unless otherwise indicated.

Figure 1 shows the quantification of the DMPO-OH entrapment adducts of the hydroxyl radical on the nitrone DMPO (50 mM) detected in the coronary effluents of ischemic cores after 3 minutes of reperfusion

The following examples illustrate the present application without limiting it.

Example 1 Competition of 3,5-seco-4-nor-cholestan-5-one oxime-3-ol with 5,5-dimethyl-1-pyrroline-1-oxide in the presence of free radicals.

The antiradical properties of the claimed products are demonstrated by conducting a competition study with a reference product belonging to the family of nitrones. Nitrones such as DMPO (5,5-dimethyl-1-pyrroline-1-oxide) are widely described as compounds having a very high reactivity towards free radicals (Novelli G. P. et al., Free Radical Res.

Common. 1986,1, 321). Nitrones trap radical species (R-; RO) and allow their observation in electron paramagnetic resonance (EPR) (Degray J. and Electron Spin Resonance, Ed N. M. Atherton, Atheaeum Press

Cambridge, 1994, 14, 246).

The incubation of DMPO (Interchim-U2469) (20 mM) in deoxygenated toluene (Sigma-Aldrich) in the presence of the tBuO (tert-butoxy) radical, generated by photolysis, allows the RPE signal to be identified and quantified by RPE. radical DMPO-tBuO. This signal is inhibited in the presence of an equimolar amount of 3,5-seco-4-ήor-cholestane oxime.

The signal in RPE allows integration as a signal area of the DMPO-tBuO adduct and thus a relative quantization of this radical entity. All experiments were performed on a Bruker ESP300 X-band (9.5GHz) at room temperature. The solutions were studied in tube

RPE in quartz.

The figures are shown in the table below.

Conclusion

The 3,5-seco-4-nor-cholestan-5-one oxime-3-ol inhibits the level of the DMPO-tBuO signal radical by about 60% and this with rapid kinetics, less than 10 minutes. The intensity of the trapping of the tBuO radical and its kinetics demonstrate the anti-radical and therefore antioxidant property of the claimed compounds.

EXAMPLE 2 Antioxidant effect of 3,5-seco-4-nor-cholestan-5-one oxime-3-ol in the oxidation model of cumene by activated oxygen.

To demonstrate the relevance of the antioxidant effect of 3,5-seco-4-nor-cholestan-5-one oxime-3-ol, the inhibition of cumene oxidation to hydroperoxycumene was studied. This test has the advantage of involving the biologically the most relevant oxidant, that is to say the oxygen gas. The oxidation of cumene at atmospheric pressure and at 37 ^° C. with oxygen is known and described in the presence of a radical initiator such as AIBN (azobisisobutyronitrile)

(Blanchard, S.S., J. Am.Chem.Soc.1959, 81, 4548). A recent publication used this reaction to rank the antioxidant potential of known products such as vitamin E (which is the universal reference), BHT

(butylatedhydroxytoluene) and other products.

In the following experiment we reproduced the same experimental conditions as those described in the publication of Becker D.A. and collaborator (J. Am Chem Chem S 2002, 124, 4678-4684). A high pressure liquid chromatography method coupled to a UV detector was used to detect cumene hydroperoxide. The column used is an Agilent Zorbax Eclipse XDB RPC8 column (150x4.6 mm) coupled to a UV detector set at 254 nm. The gradient used is detailed in the following table:

Time (min)% water% Acetonitrile Flow ml / min

0 35 65 1 .5

5 35 65 1 .5

Experimental conditions:

2 ml of cumene (AcrosOrganic) and 0.5 ml of methanol are mixed, the azobisisobutyroriitrile (AcrosOrganic) is added (2 equivalents) and the solution set at 45 ° C to accelerate the chemical reaction. The cumene hydroperoxide appears over time and is assayed by the HPLC method. A linear regression line is established to demonstrate that the quantification of the appearance of cumene hydroperoxide is possible. The results are presented in the following table:

The linear regression line obtained has the following formula: y = 0.0444x + 0.2694 with R ² = 0.994

The technique used made it possible to compare the appearance of cumene hydroperoxide in the presence of an antioxidant agent such as the claimed products and the vitamin E used as reference product.

The experimental data and percentage results of cumene oxidation are presented in the table below.

In conclusion, 3,5-seco-4-nor-cholestan-5-one oxime-3-ol reduces the oxidation of cumene by oxygen by approximately 40% and has an activity of the same order of magnitude as vitamin E under these conditions at the same concentrations.

Example 3: Pharmacokinetic study in rats with 3,5-seco-4-nor-cholestan-5-one oxime-3-ol

A pharmacokinetic study with oral administration suspended in corn oil and intravenously in solution in cremophor / ethanol / water (5%, 10%, 85%) made it possible to calculate the bioavailability of product. The determination of the product in the plasma is carried out by a method of high pressure liquid chromatography coupled with mass spectrometry.

Thus, at a dose of 500 mg / kg administered orally, the bioavailability was calculated at 6%. The circulating level of oxime of 3,5-seco-4-nor-cholestan-5-one oxime-3-ol is therefore quantifiable and demonstrates a real absorption of the product.

Example 4: Chemical stability of 3,5-seco-4-nor-cholestan-5-one oxime-3-ol

A chemical stability study under the storage conditions described in the ICH (International Conference on Harmonization of Technical Requirements for Pharmaceutical Use for Human Use) of the powdered product has demonstrated very high chemical stability. These analyzes were performed using a gas chromatography method coupled to an FID detector. This method makes it possible to quantify the impurities at a rate of 0.2%. The results (sums of impurities at each time) are presented in the following table.

No change in the quality of the product is demonstrated after 6 months of storage at 40 ^° C. and after 1 year of storage at 25 ° C.

Example 5: Antioxidant activity of 3,5-seco-4-nor-cholestan-5-one oxime-3-ol (A) in an experimental model of perfused isolated rat heart.

The animals used are male Sprague Dawley strain rats (Harlan and CERJ, France) of 250-300 g) fed ad libitum. The rats are anesthetized with an intraperitoneal injection of pentobarbital sodium (50 mg / kg body weight). The chest cavity is then opened and the heart rapidly removed and immersed in infusion fluid (Krebs-Henseleit) at 4 ° C to stop contraction.

The fat-free heart is then perfused using the Langendorff technique aortic retrograde pathway at a constant pressure of 90 cm H ₂ O. A small incision in the pulmonary artery allows for the flow and measurement of coronary effluent. time function (coronary flow). The time required for the entire operation to be completed is two to three minutes. After ablation of the left atrium, a latex balloon is inserted into the left ventricle and filled with a volume of distilled water (50-60 μl) which remains constant during the experimental protocol, connected to a pressure sensor

(GOULD) and a differential recorder allowing the measurement of the following hemodynamic parameters:

- intraventricular diastolic pressure (Pdia) - developed pressure of the left ventricle Pdev = Psystolic - Pdia

- dP / dt (first derivative of developed pressure, index of cardiac contractility in this model)

- heart rate (F)

cardiac work calculated from the relation W = Pdev x F The coronary flow as well as all the hemodynamic parameters are measured every 5 minutes.

The perfusion medium is an ionic solution of Krebs-Henseleit pH 7.35 buffered and saturated with a gaseous mixture (95% O ₂ /5% CO ₂ ), containing NaCl (119, mM), NaHCO ₃ (25 mM), KCl (5.9 mM), MgSO ₄ (1.2 mM) EDTA (0.5 mM), glucose (11 mM, core substrate) and CaCl ₂ (2.5 mM). The 3,5-seco-4-nor-cholestan-5-one oxime-3-ol compound (A) is diluted in this Krebs buffer to 1 μM of 3,5-seco-4-nor-cholestan-5-one. oxime-3-ol (A) from a 1000X solution of 30% hydroxylpropyl beta cyclodextrin in PBS. The control Krebs medium is prepared from a 30% hydroxylpropyl beta cyclodextrin 1000X solution in PBS without the compound 3,5-seco-4-nor-cholestan-5-one oxime-3-ol (A) (CD 0.03 %).

The perfused hearts of the rats followed the following protocol:

- an initial equilibration period of 30 min (CTR) - reduced flow ischemia (30% control coronary flow) 10 min (IDR)

a total ischemia of 30 min (IT) at 37 ° C.

- a reperfusion of 60 min (REP). All compounds or mixtures tested were perfused from the twentieth minute of CTR, all of NDR. They were maintained in IT at 37 ° C, thus constituting an "incubation" liquid for the ischemic myocardium, and were then further perfused throughout the reperfusion.

For EPR experiments by free radical scavenging, the hearts were perfused according to the same protocol as the previously described cores during the control and ischemia periods.

Nitrone DMPO (50 mM) is perfused at the beginning of the reperfusion at the inlet of the aorta so as to trap the free radicals produced in the coronary effluents. These effluents were collected by direct sampling into the coronary sinus at 3 minutes of reperfusion and then preserved in liquid nitrogen before analysis by RPE adducts formed on this nitrone. Spin trappinq on DMPO in coronary effluents

The EPR signals characteristic of the DMPO-OH adduct are detected in the effluents at the third minute of reperfusion in the presence of DMPO (50 mM).

With the infusion of the compound 3,5-seco-4-nor-cholestan-5-one oxime-3-ol

(A), there was a significant and significant (p <0.05) decrease in extracellular production of free radical trapping adducts formed in the myocardium and trapped on DMPO. These adducts are sufficiently persistent to be detected by, RPE.

The statistical analysis of the results obtained on two groups of six hearts shows that the infusion with the compound 3,5-seco-4-nor-cholestan-5-one oxime-3-ol (A) 1 μM provides a significant protection against to the vehicle (Figure 1).

In conclusion, the compound 3,5-seco-4-nor-cholestan-5-one oxime-3-ol (A) reduces the release of oxygen radical species.

Claims

1. Use of at least one oxime derivative of 3,5-seco-4-nor-cholestane or one of its addition salts with the acceptable acids, or one of its esters or one of the salts adding said esters with the acceptable acids as an antioxidant.

2. Use according to claim 1 of at least one oxime derivative of 3,5-seco-4-nor-cholestane corresponding to formula I

in which

X and Y taken together an oxime radical (= NOH) where X represents a hydroxyl and Y represents a hydrogen atom,

B represents a hydroxyl radical and C and D, which may be identical or different, represent a hydrogen atom, or a linear or branched alkyl radical comprising from 1 to 4 carbon atoms, or

B and C taken together represent a keto function and D a methyl, hydroxyl or methylamine radical, or

B and C represent a hydrogen atom and D a methylamine radical, or

- B and C taken together represent an oxime group and D a methyl radical, and

R represents a linear or branched alkyl radical comprising from 1 to 10 carbon atoms.

Use according to Claim 2, characterized in that the alkyl radical linear or branched from 1 to 4 carbon atoms is a methyl, ethyl, propyl or isopropyl radical, preferably a methyl or ethyl radical and particularly a methyl radical.

4. Use according to any one of claims 1 to 3, characterized in that the oxime derivative of 3,5-seco-4-nor-cholestane is chosen from compounds for which

B represents a hydroxyl radical and C and D represent a hydrogen atom, or C and D represent 2 linear or branched alkyl radicals of 1 to 4 carbon atoms; OR

- B together with C represents a keto function and D represents a methyl, hydroxyl, methyl amine radical; or

B represents a hydroxyl group, and C and D represent a hydrogen atom, or C and D represent 2 linear or branched alkyl radicals of 1 to 4 carbon atoms, or C represents a hydrogen atom and D represents an alkyl radical. linear or branched from 1 to 4 carbon atoms; or - B and C represent a hydrogen atom and D a methyl amino group; or

- B together with C represent an oxime group, and D represents a methyl radical. 5. Use according to any one of claims 2 to 4, characterized in that the linear or branched alkyl radical of 1 to 10 carbon atoms is selected from a 2-methyl-3-ethyl heptane, 3-ethyl heptane, 3-methylheptane, preferably a 2-ethylheptane radical and particularly the 2-methylheptane radical of the formula (II) cholestane

6. Use according to any one of claims 1 to 5, characterized in that the compounds of formula I correspond to formula III

in which B, C, D, X and Y have the meaning already indicated.

7. Use according to any one of claims 1 to 6, characterized in that the oxime derivative of 3,5-seco-4-nor-cholestane is selected from compounds for which X together with Y represents a function oximes.

8. Use according to any one of claims 1 to 7, characterized in that the oxime derivative of 3,5-seco-4-nor-cholestane is selected from 3,5-seco-4-nor-cholestan-5 -one oxime-3-ol,

3,5-seco-4-nor-cholestan-5-one oxime-3-methyl alcohol,

3,5-seco-4-nor-cholestan-5-one oxime-3-dimethyl alcohol.

9. Use according to any one of claims 1 to 8, as antioxidants in the cosmetics field.

10. Use according to claim 9 for combating oxidative stress.

11. Use according to any one of claims 9 or 10, for treating aging, particularly cutaneous aging.

12. Use according to claim 11 for treating fine lines and deep wrinkles, changes in skin tone, the dry and rough appearance of the skin, loss of firmness and / or tone of the skin.

13. Use according to any one of claims 1 to 8, as antioxidants in the food field.

14. Use according to claim 13 as a dietary supplement. 15. Use according to any one of claims 1 to 8 as antioxidant preservatives, especially in cosmetics, food and pharmaceuticals. 16. Use according to any one of claims 1 to 15, the derivatives oxime of 3,5-seco-4-nor-cholestane being used alone or as a mixture, optionally in combination with one or more other compounds known for their antioxidant properties.